Home > Insider Trading > Filing (0001209191-17-066238)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1269021	Portola Pharmaceuticals Inc	PTLA	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1302390	Ward Henry Wolff	C/O Portola Pharmaceuticals, Inc. 270 East Grand Ave. South San Francisco CA 94080		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-10-05	12,000	$5.30	12,000	No	4	M	Indirect	By Henry & Marian Wolff 1999 Revoc. Trust
Common Stock	Disposition	2017-12-15	11,300	$46.95	700	No	4	S	Indirect	By Henry & Marian Wolff 1999 Revoc. Trust
Common Stock	Disposition	2017-12-15	700	$47.77	0	No	4	S	Indirect	By Henry & Marian Wolff 1999 Revoc. Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Indirect	By Henry & Marian Wolff 1999 Revoc. Trust
No	4	S	Indirect	By Henry & Marian Wolff 1999 Revoc. Trust
No	4	S	Indirect	By Henry & Marian Wolff 1999 Revoc. Trust

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2017-10-05	12,000	$0.00	12,000	$5.30

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2007-11-15	2017-11-14	No	4	M	Direct

Footnotes

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 11, 2017.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.44 to $47.38, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.55 to $47.93, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
Mr. Wolff exercised these shares through a cash exercise and transferred the shares following the exercise into the Henry & Marian Wolff 1999 Revocable Trust for which Mr. Wolff is a trustee.